About Acusphere
Acusphere is a specialty pharmaceutical company, primarily focused on the development of Imagify, a cardiovascular drug for the detection of coronary artery disease. Acusphere is in the process of seeking regulatory approval of Imagify in Europe, and negotiating a Special Protocol Assessment with FDA for an additional trial required for US approval.
January 20, 2012
Acusphere, Inc. Stockholders Approve Reverse Stock Split at Special Meeting of Stockholders
December 19, 2011
Acusphere, Inc. Issues Letter to Shareholders
June 08, 2011
Acusphere, Inc. reaches Special Protocol Assessment Agreement with FDA for Imagify™ Phase 3 Placebo-Controlled Trial
